Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 (Sonidegib) Plus Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT02254551Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2015
- Primary completion
- Oct 2015
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of sonidegib in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Jan 2015; status: terminated.
02
Drugs
sonidegib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02254551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254551.